MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Legend Biotech Corp ADR

Fechado

SetorSaúde

33.29 5.75

Visão Geral

Variação de preço das ações

24h

Atual

Mín

30.96

Máximo

33.51

Indicadores-chave

By Trading Economics

Rendimento

161M

41M

Vendas

26M

187M

EPS

0.14

Margem de lucro

21.719

Funcionários

2,600

EBITDA

162M

52M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+164.47% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-30M

6.4B

Abertura anterior

27.54

Fecho anterior

33.29

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Legend Biotech Corp ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2024, 11:36 UTC

Ganhos

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11 de mar. de 2025, 11:09 UTC

Ganhos

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 de mar. de 2025, 11:08 UTC

Ganhos

Legend Biotech 4Q EPS 7c >LEGN

11 de mar. de 2025, 11:00 UTC

Ganhos

Legend Biotech 4Q Rev $186.5M >LEGN

12 de nov. de 2024, 12:06 UTC

Ganhos

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 de nov. de 2024, 12:05 UTC

Ganhos

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 de nov. de 2024, 12:00 UTC

Ganhos

Legend Biotech 3Q Rev $160.2M >LEGN

9 de ago. de 2024, 11:02 UTC

Ganhos

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 de ago. de 2024, 11:01 UTC

Ganhos

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 de ago. de 2024, 11:01 UTC

Ganhos

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 de ago. de 2024, 11:00 UTC

Ganhos

Legend Biotech 2Q Rev $186.5M >LEGN

26 de jul. de 2024, 11:01 UTC

Ganhos

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13 de mai. de 2024, 11:02 UTC

Ganhos

Legend Biotech 1Q Loss/Shr 16c >LEGN

13 de mai. de 2024, 11:02 UTC

Ganhos

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Comparação entre Pares

Variação de preço

Legend Biotech Corp ADR Previsão

Preço-alvo

By TipRanks

164.47% parte superior

Previsão para 12 meses

Média 83.36 USD  164.47%

Máximo 95 USD

Mínimo 62 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Legend Biotech Corp ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

13

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.39 / 35.05Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.